Alto Neuroscience Stock Performance
| ANRO Stock | 16.52 0.19 1.14% |
On a scale of 0 to 100, Alto Neuroscience holds a performance score of 10. The firm shows a Beta (market volatility) of 1.1, which signifies a somewhat significant risk relative to the market. Alto Neuroscience returns are very sensitive to returns on the market. As the market goes up or down, Alto Neuroscience is expected to follow. Please check Alto Neuroscience's value at risk, as well as the relationship between the skewness and price action indicator , to make a quick decision on whether Alto Neuroscience's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Alto Neuroscience are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting basic indicators, Alto Neuroscience displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.36 | Five Day Return 16.45 | Year To Date Return 0.72 | Ten Year Return (19.28) | All Time Return (19.28) |
1 | Alto Neuroscience 4 Shots At Success In CNS Diseases In 2026 - Seeking Alpha | 11/28/2025 |
2 | Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Business Wire | 12/03/2025 |
3 | Alto Neuroscience Sets New 1-Year High Heres Why | 12/15/2025 |
4 | Will Alto Neuroscience Inc. stock sustain uptrend momentum - 2025 Winners Losers Daily Stock Trend Watchlist - DonanmHaber | 12/19/2025 |
5 | Alto Neuroscience, Inc. is definitely on the radar of institutional investors who own 33 percent of the company | 12/26/2025 |
6 | Acquisition by Sanchez Ramiro of 3806 shares of Alto Neuroscience at 16.59 subject to Rule 16b-3 | 01/02/2026 |
7 | Why Alto Neuroscience Inc. stock could be next big winner - 2025 Growth vs Value Accurate Buy Signal Notifications - ulpravda.ru | 01/08/2026 |
8 | Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology | 01/13/2026 |
9 | Alto Neuroscience, Inc. Short Interest Update | 01/20/2026 |
10 | Alto Neuroscience, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat | 02/09/2026 |
| Begin Period Cash Flow | 82.5 M | |
| Total Cashflows From Investing Activities | -2.1 M |
Alto Neuroscience Relative Risk vs. Return Landscape
If you would invest 1,211 in Alto Neuroscience on November 14, 2025 and sell it today you would earn a total of 460.00 from holding Alto Neuroscience or generate 37.99% return on investment over 90 days. Alto Neuroscience is currently generating 0.6573% in daily expected returns and assumes 4.9521% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Alto, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alto Neuroscience Target Price Odds to finish over Current Price
The tendency of Alto Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 16.52 | 90 days | 16.52 | about 33.55 |
Based on a normal probability distribution, the odds of Alto Neuroscience to move above the current price in 90 days from now is about 33.55 (This Alto Neuroscience probability density function shows the probability of Alto Stock to fall within a particular range of prices over 90 days) .
Alto Neuroscience Price Density |
| Price |
Predictive Modules for Alto Neuroscience
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Alto Neuroscience. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Alto Neuroscience Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Alto Neuroscience is not an exception. The market had few large corrections towards the Alto Neuroscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Alto Neuroscience, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Alto Neuroscience within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.66 | |
β | Beta against Dow Jones | 1.10 | |
σ | Overall volatility | 2.19 | |
Ir | Information ratio | 0.12 |
Alto Neuroscience Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Alto Neuroscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Alto Neuroscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Alto Neuroscience appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (61.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alto Neuroscience generates negative cash flow from operations | |
| Alto Neuroscience has a frail financial position based on the latest SEC disclosures | |
| About 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Alto Neuroscience, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat |
Alto Neuroscience Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Alto Stock often depends not only on the future outlook of the current and potential Alto Neuroscience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alto Neuroscience's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24.6 M | |
| Cash And Short Term Investments | 168.2 M |
Alto Neuroscience Fundamentals Growth
Alto Stock prices reflect investors' perceptions of the future prospects and financial health of Alto Neuroscience, and Alto Neuroscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alto Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 412.86 M | ||||
| Shares Outstanding | 31.07 M | ||||
| Price To Book | 4.69 X | ||||
| EBITDA | (68.61 M) | ||||
| Net Income | (61.43 M) | ||||
| Total Debt | 16.94 M | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (47.42 M) | ||||
| Earnings Per Share | (2.30) X | ||||
| Market Capitalization | 517.25 M | ||||
| Total Asset | 177.54 M | ||||
| Retained Earnings | (138.4 M) | ||||
| Working Capital | 159.33 M | ||||
About Alto Neuroscience Performance
By examining Alto Neuroscience's fundamental ratios, stakeholders can obtain critical insights into Alto Neuroscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alto Neuroscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.47) | (0.44) |
Things to note about Alto Neuroscience performance evaluation
Checking the ongoing alerts about Alto Neuroscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alto Neuroscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alto Neuroscience appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (61.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alto Neuroscience generates negative cash flow from operations | |
| Alto Neuroscience has a frail financial position based on the latest SEC disclosures | |
| About 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Alto Neuroscience, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat |
- Analyzing Alto Neuroscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alto Neuroscience's stock is overvalued or undervalued compared to its peers.
- Examining Alto Neuroscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alto Neuroscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alto Neuroscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alto Neuroscience's stock. These opinions can provide insight into Alto Neuroscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.